Sec Form 3 Filing - SBI INVESTMENT KOREA CO., LTD. @ Peak Bio, Inc. - 2022-12-13

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SBI INVESTMENT KOREA CO., LTD. 2. Issuer Name and Ticker or Trading Symbol Peak Bio, Inc. [ PKBO] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 14TH FL., NC TOWER, 509,, TEHERAN-RO, GANGNAM-GU 3. Date of Earliest Transaction (MM/DD/YY) 12/13/2022 (Street) SEOUL, M5 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 3,621,489 ( 1 ) D ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SBI INVESTMENT KOREA CO. , LTD. 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X SBI CROSS-BORDER ADVANTAGE FUND 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X SBI HEALTHCARE FUND I 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X 2019 SBI JOB CREATION FUND 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X IKBC-SBI BIO FUND 1 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X SBI KIS 2016-1 FUND 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X 2014 KIF-SBI IT INVESTMENT FUND 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X GLOBAL GATEWAY FUND 1 14TH FL., NC TOWER, 509, TEHERAN-RO, GANGNAM-GU SEOUL, M5 X Signatures /s/ Joon-Hyo Lee, Co-CEO Eiichiro So, Co-CEO, SBI Investment Korea Co., Ltd. 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Authorized Persons, SBI Cross-border Advantage Fund 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Authorized Persons, SBI Healthcare Fund 1 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Co-CEO Eiichiro So, Authorized Persons, IBKC-SBI Bio Fund 1 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Co-CEO of SBI Investment Korea Co., Ltd., Authorized Person, SBI KIS 2016-1 Fund 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Authorized Persons, 2014 KIF-SBI IT Investment Fund 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Authorized Persons, Global Gateway Fund 1 02/28/2023 Signature of Reporting Person Date /s/ Joon-Hyo Lee, Eiichiro So, Authorized Persons, 2019 SBI Job Creation Fund 02/28/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Consists of 320,206 shares of common stock held by SBI Investment KOREA Co., Ltd. ("SBI"), 251,418 shares of common stock held by SBI Cross-border Advantage Fund, an affiliate of SBI, 599,202 shares of common stock held by SBI Healthcare Fund 1, an affiliate of SBI, 1,601,067 shares of common stock held by IBKC-SBI Bio Fund 1, an affiliate of SBI, 83,800 shares common stock held by SBI KIS 2016-1 Fund, an affiliate of SBI, 167,600 shares of common stock held 2014 KIF -SBI IT Investment Fund, an affiliate of SBI, 419,017 shares of common stock held by Global Gateway Fund 1, an affiliate of SBI and 179,179 shares of common stock held by 2019 SBI Job Creation Fund, an affiliate of SBI. These shares of common stock were acquired in the business combination consummated between Peak Bio, Inc. (f/k/a Ignyte Acquisition Corp.), Ignyte Korea Co., Ltd. and Peak Bio Co., Ltd. ( 2 )This Form 3 is being filed jointly by SBI, SBI Cross-border Advantage Fund, SBI Healthcare Fund 1, IBKC-SBI Bio Fund 1, SBI KIS 2016-1 Fund, 2014 KIF-SBI IT Investment Fund, Global Gateway Fund 1 and 2019 SBI Job Creation Fund. Each Reporting Person disclaims beneficial ownership of these securities except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purpose of Section 16 or any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.